Claims for Patent: 8,637,451

Summary for Patent: 8,637,451

Title:	Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Abstract:	A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
Inventor(s):	Shailubhai; Kunwar (Audubon, PA), Nikiforovich; Gregory (St. Louis, MO), Jacob; Gary S. (New York, NY)
Assignee:	Synergy Pharmaceuticals Inc. (New York, NY)
Application Number:	13/339,785
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,637,451
Patent Claims:	1. A method for stimulating water transport in the gastrointestinal tract in a patient comprising administering to said patient a guanylate cyclase receptor agonist peptide consisting of SEQ ID NO:20, wherein said peptide is administered in an amount sufficient to induce cGMP production in a gastrointestinal epithelial cell and wherein said peptide is (4,12; 7,15) bicycle. 2. The method of claim 1, further comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with said guanylate cyclase receptor agonist peptide, wherein said inhibitor of cGMP-dependent phosphodiesterase is selected from the group consisting of sulindac sulfone, zaprinast, and motapizone. 3. The method of claim 1, wherein said peptide is formulated as a powder.